AffiliationDepartment of Surgery, Cork University Hospital, Cork, Ireland., email@example.com
Anti-Bacterial Agents/therapeutic use
Clinical Trials as Topic
Drug Resistance, Multiple, Bacterial/drug effects/immunology
MetadataShow full item record
CitationSurgeon. 2006 Dec;4(6):355-61.
JournalThe surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
AbstractWhile antibiotics address the root cause of sepsis--that of pathogen infection--they fail to provide an adequate cure for the condition. Currently, 30% to 50% of septic patients die, and this figure is likely to increase in line with the proliferation of multi-drug resistant bacteria. With an increased understanding of the immune response, it has been proposed that modulation of this defence mechanism offers the best hope of cure. Many entry-points in the immune system have been identified and targeted therapies have been developed,but why are these not in routine clinical practice? This review examines the latest evidence for the use of immuno-modulating drugs, obtained from human clinical trials. We discuss cytokine-based therapies, steroids and anti-coagulants. Finally, consideration is given as to why successful therapies in the laboratory, and in vivo models, do not automatically translate into clinical benefit
- [Development of antituberculous drugs: current status and future prospects].
- Authors: Tomioka H, Namba K
- Issue date: 2006 Dec
- Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?
- Authors: Dyson A, Singer M
- Issue date: 2009 Jan
- Clinically-oriented therapies in sepsis: a review.
- Authors: Dubois MJ, Vincent JL
- Issue date: 2000
- Mediator-specific therapies for the systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock: present and future approaches.
- Authors: Hazinski MF
- Issue date: 1994 Jun
- Why do animal models (sometimes) fail to mimic human sepsis?
- Authors: Esmon CT
- Issue date: 2004 May